<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="371369">
  <stage>Registered</stage>
  <submitdate>22/11/2016</submitdate>
  <approvaldate>17/01/2017</approvaldate>
  <actrnumber>ACTRN12617000096358</actrnumber>
  <trial_identification>
    <studytitle>Subthreshold micropulse yellow (577nm) laser versus half-dose photodynamic therapy for central serous chorioretinopathy : a randomized controlled pilot study </studytitle>
    <scientifictitle>Subthreshold micropulse yellow (577nm) laser versus half-dose photodynamic therapy for central serous chorioretinopathy : a randomized controlled pilot study </scientifictitle>
    <utrn>U1111-1190-2544 </utrn>
    <trialacronym />
    <secondaryid>None</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Central serous chorioretinopathy</healthcondition>
    <conditioncode>
      <conditioncode1>Eye</conditioncode1>
      <conditioncode2>Diseases / disorders of the eye</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Half-dose Photodynamic therapy
The Photodynamic therapy (PDT)(intravenous infusion) will be performed using half-dose verteporfin (Visudyne; Novartis). For this, 3 mg/m2 of verteporfin will be infused over 10 minutes, and 15 minutes after beginning the infusion, the laser treatment will be begun. The total light energy delivered to the area of hyperpermeability is 50 J/cm2 over 83 seconds. The area of irradiation will be set to cover the hyperfluorescent area measured in the images recorded during the middle to late phases of indocyanine green angiography (ICGA).

If both eyes meet the inclusion criteria, only the right eye will be included in bilateral cases.

In photodynamic therapy, a light-sensitive medicine called verteporin (Visudyne)
is injected into the bloodstream. Laser light is then shone into the eye, which activates the medicine and the abnormal choroidal blood vessels is treated.  In micropulse laser, a continuous-wave laser beam is chopped into a train of tiny, repetitive, low energy pulses, to treat the areas of diseased retinal pigment epithelium (RPE), inducing resorption of the subretinal fluid.

Patients in the PDT group will be considered for retreatment every 6 months whereas patients in the micropulse laser group will be considered for retreatment every 3 months. Patients who have persistent subretinal fluid after 3 treatments of micropulse laser will receive half-dose photodynamic therapy as rescue therapy, 3 months after the third micropulse laser treatment. In the PDT group, patient who have persistent subretinal fluid 6 months after the initital treatment will receive second half-dose photodynamic therapy.</interventions>
    <comparator>Subthreshold  micropulse yellow laser

The focal leaking points and areas of hyperpermeability shown in pretreatment FA and ICGA will be used to guide the subthreshold micropulse laser therapy with 577nm yellow laser (IRIDEX IQ 577 laser, USA) delivered through the PDT laser lens (Volk Optical Inc, Mentor, OH, USA). Micropulse laser with spot size of 200 micro meter, 0.2 s exposure time, 400mW, a duty cycle of 5%, will be applied in 7x7 treatment grid pattern over areas of focal and diffuse RPE leak, using TxCellTM Scanning Laser Delivery System.

In the micropulse laser group, 30 ml normal saline will be infused instead of verteporfin, before application of micropulse laser. After treatment, you need to wear protective spectacles and avoid strong light for 2 days. You will need to attend clinic follow up visits at Hong Kong Eye Hospital or CUHK Eye Centre at 1, 3, 6, 9 and 12 months after the treatment. All investigations will be performed during your routine follow-up visits. No extra visits are necessary. Upon follow up, you will you will receive microperimtery and imaging with optical coherence tomography (OCT). Fluorescein angiography (FA) and indocyanine green angiography (ICGA) will be performed for patients with persistent subretinal fluid after the treatment, as decided by the doctors.</comparator>
    <control>Active</control>
    <interventioncode>Treatment: Devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>proportion of eyes with complete absorption of subretinal fluid (SRF) at 12 months

The absorption of subretinal fluid is assessed using an optical coherence tomography (OCT) scan</outcome>
      <timepoint>12 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Serial changes in logMAR BCVA

Using a logMAR visual acuity chart</outcome>
      <timepoint>Using a logMAR visual acuity chart to see serial changes in logMAR BCVA in 1, 3, 6, 9 and 12 months. 
</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Serial changes in central foveal thickness

Using optical coherence tomography (OCT) scan</outcome>
      <timepoint>Using optical coherence tomography (OCT) scan to see serial changes in central foveal thickness in 1, 3, 6, 9 and 12 months. 
</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Serial changes in OCT morphological features

Using optical coherence tomography (OCT) scan</outcome>
      <timepoint>Using optical coherence tomography (OCT) scan to see serial changes in OCT morphological features in 1, 3, 6, 9 and 12 months. </timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Serial changes in microperimetry sensitivity

Using a microperimeter</outcome>
      <timepoint>Using a microperimeter to see serial changes in microperimetry sensitivity in 1, 3, 6, 9 and 12 months. </timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Serial changes in FA and ICGA

Serial fluorescein angiogram and indocyanine green angiogram</outcome>
      <timepoint>using serial fluorescein angiogram and indocyanine green angiogram to see serial changes in FA and ICGA in  1, 3, 6, 9 and 12 months. </timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>The time needed for a complete resolution of the SRF after the primary treatment

Using optical coherence tomography (OCT) scan</outcome>
      <timepoint>Using optical coherence tomography (OCT) scan to see  the time needed for a complete resolution of the SRF after the primary treatment in  1, 3, 6, 9 and 12 months. </timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>The time to a recurrence of an SRF

Using optical coherence tomography (OCT) scan</outcome>
      <timepoint>Using optical coherence tomography (OCT) scan to see the time to a recurrence of an SRF in   1, 3, 6, 9 and 12 months. </timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Systemic and ocular complications during the study.

No additional tools or tests as this is a clinical finding </outcome>
      <timepoint>No additional tools or tests would be used for looking at systemic and ocular complications during the study in   1, 3, 6, 9 and 12 months
</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>(1)	CSCR is defined by idiopathic, single, or multiple serous detachments of the neurosensory retina in the macular area associated with RPE changes or RPE leaks on fluorescein angiography (FA) and visual symptoms for less than 3 months(acute CSCR) or more than 3 months (chronic CSCR)
(2)	Patient with 18 years or older
(3)	Absence of spontaneous resolution or improvement induced by empirical treatment such as acetazolamide or ketoconazole
(4)	Presence of written informed consent </inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>(1)	Any previous treatment, including PDT and focal thermal laser photocoagulation, for CSCR
(2)	Iatrogenic CSC caused by corticosteroids
(3)	FA or ICGA findings of CNV, polyploidal choroidal vasculopathy (PCV)
(4)	Other maculopathy on clinical examination, FA, indocyanine green angiography (ICGA)
(5)	Media opacity such as cataract that could interfere with adequate acquisition of OCT, FA and ICGA images</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Patients will be randomized into the half-dose PDT group or the subthreshold micropulse yellow (577-nm) laser group at a ratio of 1:1. The randomization sequence will be generated using a computerized randomization table kept centrally by a research assistant. All patients and investigators will be masked to the treatment allocation group. Assessors performing the follow-up assessments also will be masked to the patient allocation group. In the micropulse laser group, 30 ml normal saline will be infused instead of verteporfin, before application of micropulse laser. The infusion syringes will be wrapped externally with aluminum foil. After treatment, all patients will be given protective spectacles and will be instructed to avoid strong light for 3 days.</concealment>
    <sequence>The randomization sequence will be generated using a computerized randomization table kept centrally by a research assistant.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods>Statistical analysis was performed using SPSS software version 20.0 (SPSS, Inc., Chicago, IL). Analysis is performed as intention to treat. Comparisons of categorical variables between the 2 groups are performed using the chi-square test or the Fisher exact test, and continuous variables are compared using a 2-tailed t test or MannWhitney U test. A P value of equal/ not more than 0.05 is considered as statistically significant. </statisticalmethods>
    <masking1>True</masking1>
    <masking2>True</masking2>
    <masking3>True</masking3>
    <masking4>True</masking4>
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/11/2016</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>120</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Hong Kong</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Brelen Marten Erik </primarysponsorname>
    <primarysponsoraddress>Department of Ophthalmology &amp; Visual Sciences
The Chinese University of Hong Kong 
4/F Hong Kong Eye Hospital
147K Argyle Street, Mongkok,
Hong Kong SAR</primarysponsoraddress>
    <primarysponsorcountry>Hong Kong</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Health and Medical Research Fund </fundingname>
      <fundingaddress>Research Fund Secretariat 
Research Office
Food and Health Bureau
9/F, Rumsey Street Multi-storey Carpark Building
2 Rumsey Street, Sheung Wan
Hong Kong.</fundingaddress>
      <fundingcountry>Hong Kong</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Purpose
This randomized controlled pilot clinical trial aims to compare the efficacy and safety of half-dose photodynamic therapy(PDT) and subthreshold micropulse yellow (577-nm) laser in central serous chorioretinopathy (CSCR).

Methods
This will be a prospective, double-masked, randomized controlled study. Patients with CSCR attending at Hong Kong Eye Hospital between January 2016 and December 2016 will be recruited in the study. If both eyes meet the inclusion criteria, only the right eye will be included in bilateral cases. Patients will be randomized into the half-dose PDT group or the subthreshold micropulse yellow (577-nm) laser group at a ratio of 1:1.

All patients and investigators will be masked to the treatment allocation group. Assessors performing the follow-up assessments also will be masked to the patient allocation group. 

Half-dose Photodynamic therapy
The PDT will be performed using half-dose verteporfin (Visudyne; Novartis AG). For this, 3 mg/m2 of verteporfin will be infused over 10 minutes, and 15 minutes after beginning the infusion, the laser treatment will be begun. The total light energy delivered to the area of hyperpermeability is 50 J/cm2 over 83 seconds.

Subthreshold micropulse yellow laser
The focal leaking points and areas of hyperpermeability will be treated with the subthreshold micropulse laser therapy with 577nm yellow laser (IRIDEX IQ 577 laser, USA). In the micropulse laser group, 30 ml normal saline will be infused instead of verteporfin, before application of micropulse laser. 

Baseline and follow-up examinations
Patients will be assessed at baseline and followed up at 1, 3, 6, 9 and 12 months after the treatment. At the baseline and all post-treatment visits, best-corrected visual acuity (BCVA), will be measured. The optical coherence topography (OCT) (Topcon DRI OCT, Triton OCT, Japan; Spectralis OCT, Heidelberg Engineering Inc., Heidelberg, Germany) and microperimtery will be performed before the treatment as well as at each clinical visit. Patients with persistent subretinal fluid will have further fluorescein angiography (FA) and indocyanine green angiography (ICGA) as decided by the assessors. 

Retreatment will be considered if the patients meet two of the three following criteria: decreased visual acuity of at least one line from baseline, presence of subretinal fluid on OCT, and significant leakage on angiography. Patients in the PDT group will be considered for retreatment every 6 months whereas patients in the micropulse laser group will be considered for retreatment every 3 months. Patients who have persistent SRF after 3 treatments of micropulse laser will receive half-dose photodynamic therapy as rescue therapy, 3 months after the third micropulse laser treatment.

The primary outcome of the study is the proportion of eyes with complete absorption of subretinal fluid (SRF) at 12 months. Secondary outcome measures included serial changes in logMAR BCVA, central foveal th</summary>
    <trialwebsite>None</trialwebsite>
    <publication>None</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes>None</publicnotes>
    <ethicscommitee>
      <ethicname>Kowloon Central Kowloon East Cluster</ethicname>
      <ethicaddress>Block S, Queen Elizabeth Hospital
30 Gascoigne Road
KOWLOON
</ethicaddress>
      <ethicapprovaldate>12/01/2016</ethicapprovaldate>
      <hrec>KC/KE-15-0192/FR-3</hrec>
      <ethicsubmitdate>5/11/2015</ethicsubmitdate>
      <ethiccountry>Hong Kong</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>The Joint Chinese University of Hong Kong â€“ New Territories East Cluster Clinical Research Ethics Committee</ethicname>
      <ethicaddress>8/F, Lui Che Woo Clinical Sciences Building, 
Prince of Wales Hospital, Shatin, Hong Kong</ethicaddress>
      <ethicapprovaldate>22/12/2015</ethicapprovaldate>
      <hrec>CRE-2015.573</hrec>
      <ethicsubmitdate>15/10/2015</ethicsubmitdate>
      <ethiccountry>Hong Kong</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment>
    <filepath>http://www.anzctr.org.au/AnzctrAttachments/371369-530-KCKE &amp; NTEC Approval.pdf</filepath>
    <filepath>http://www.anzctr.org.au/AnzctrAttachments/371369-KCKE-Protocol - micropulse vs half dose PDT in chronic CSCR_20151124.pdf</filepath>
    <filepath>http://www.anzctr.org.au/AnzctrAttachments/371369-KCKE-Consent Info_English_KCC 20151124_clean.pdf</filepath>
    <filepath>http://www.anzctr.org.au/AnzctrAttachments/371369-KCKE-3.1 Informed Consent Form (Chi) - 20151218_clean.pdf</filepath>
    <filepath>http://www.anzctr.org.au/AnzctrAttachments/371369-NTEC-Consent Info_Chinese_PWH 20151203_clean.pdf</filepath>
    <filepath>http://www.anzctr.org.au/AnzctrAttachments/371369-NTEC-Consent Info_English_PWH 20151203_clean.pdf</filepath>
    <filepath>http://www.anzctr.org.au/AnzctrAttachments/371369-NTEC-Protocol - micropulse vs half dose PDT in CSCR_20151203.pdf</filepath>
  </attachment>
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Brelen Marten Erik</name>
      <address>Department of Ophthalmology &amp; Visual Sciences,
3/F, Hong Kong Eye Hospital
147K Argyle Street
KOWLOON


</address>
      <phone>+852-39435825</phone>
      <fax />
      <email>marten.brelen@cuhk.edu.hk</email>
      <country>Hong Kong</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Miss</title>
      <name>Janice Wong</name>
      <address>Department of Ophthalmology &amp; Visual Sciences,
3/F, Hong Kong Eye Hospital
147K Argyle Street
KOWLOON</address>
      <phone>+852-39435825</phone>
      <fax />
      <email>janicewong@cuhk.edu.hk</email>
      <country>Hong Kong</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Brelen Marten Erik</name>
      <address>Department of Ophthalmology &amp; Visual Sciences,
3/F, Hong Kong Eye Hospital
147K Argyle Street
KOWLOON</address>
      <phone>+852-39435825</phone>
      <fax />
      <email>marten.brelen@cuhk.edu.hk</email>
      <country>Hong Kong</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Miss</title>
      <name>Janice Wong</name>
      <address>Department of Ophthalmology &amp; Visual Sciences,
3/F, Hong Kong Eye Hospital
147K Argyle Street
KOWLOON</address>
      <phone>852-39435825</phone>
      <fax />
      <email>janicewong@cuhk.edu.hk</email>
      <country>Hong Kong</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>